11.06.14
Plymouth Township, Mich.-based Delphinus Medical Technologies Inc. has named Shawn O’Brien its new vice president of finance, adding to recent the expansion of its executive team. The company is in the development stage of a new breast imaging technology, Softvue.
O’Brien comes to Delphinus having a successful career as a financial professional with extensive experience across a variety of corporate functions, most recently at CytoPherx of Ann Arbor, Mich. In addition to spear-heading all aspects of fiscal operations, he was responsible for leading the project management team, including clinical trial guidance, and administering vendor relations. With his direction, the company realized sizable proceeds from on-time and under-budget project completions, based on targeted revenue-sparing strategies and focused implementation. While at Kux Architectural Products of Canton, Mich., O’Brien was promoted to head of finance, advancing through successively responsible positions at the company. He began his professional career as controller at Advanced Material Process Corporation of Wayne, Mich.
“We are very pleased that Shawn has joined our team,” said Mark J. Forchette, president and CEO of Delphinus. “We are entering an important growth phase, and his appointment is key as we develop a strong foundation to accelerate our strategies. Shawn’s contribution, based on his successful track record of knowledge and experience, will be critical as we move forward in our commitment to bring transformative advances in breast cancer screening with our Softvue technology.”
O’Brien received his baccalaureate degree in accounting from University of Michigan, Flint, Mich. He earned his MBA the same institution.
Softvue is powered with circular, volumetric transducer technology. It Softvue images the entire breast in a continuous 360 degree scan sequence, moving from the back of the breast to the front, creating a cross-sectional image map. The procedure is streamlined, averaging two minutes per breast, and captures reflected echoes and the signals transmitted through the tissue. The technology is designed to provide a consistent and uniform exam without reliance on operator skill and technique. The device is not meant as a replacement for screening mammography.
O’Brien comes to Delphinus having a successful career as a financial professional with extensive experience across a variety of corporate functions, most recently at CytoPherx of Ann Arbor, Mich. In addition to spear-heading all aspects of fiscal operations, he was responsible for leading the project management team, including clinical trial guidance, and administering vendor relations. With his direction, the company realized sizable proceeds from on-time and under-budget project completions, based on targeted revenue-sparing strategies and focused implementation. While at Kux Architectural Products of Canton, Mich., O’Brien was promoted to head of finance, advancing through successively responsible positions at the company. He began his professional career as controller at Advanced Material Process Corporation of Wayne, Mich.
“We are very pleased that Shawn has joined our team,” said Mark J. Forchette, president and CEO of Delphinus. “We are entering an important growth phase, and his appointment is key as we develop a strong foundation to accelerate our strategies. Shawn’s contribution, based on his successful track record of knowledge and experience, will be critical as we move forward in our commitment to bring transformative advances in breast cancer screening with our Softvue technology.”
O’Brien received his baccalaureate degree in accounting from University of Michigan, Flint, Mich. He earned his MBA the same institution.
Softvue is powered with circular, volumetric transducer technology. It Softvue images the entire breast in a continuous 360 degree scan sequence, moving from the back of the breast to the front, creating a cross-sectional image map. The procedure is streamlined, averaging two minutes per breast, and captures reflected echoes and the signals transmitted through the tissue. The technology is designed to provide a consistent and uniform exam without reliance on operator skill and technique. The device is not meant as a replacement for screening mammography.